Want to see SE:HNSA full AI Analyst Report?

Hansa Biopharma AB (HNSA) Earnings Dates, Call Summary & Reports

Q: What is the P/E ratio of Hansa Biopharma AB stock?

The P/E ratio of {name} is N/A.

17 Followers

Earnings Data

Report Date

Jul 22, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.34

Last Year’s EPS

-2.53

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 23, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

Balanced call: significant positive developments on financing, regulatory progress (BLA review, PAES lock, ConfIdeS presentation), promising next-generation asset data (5487), and concrete market-access wins (Catalonia, German KOL guidance) are offset by a steep revenue decline (‑48% Y/Y), ongoing high cash burn and operating losses, and continued structural volatility in European organ allocation. Management emphasizes stabilization actions completed and expects benefits to materialize over coming months, but short-term revenue predictability remains limited.

Company Guidance

Management said it will not give detailed full‑year guidance but provided operational and financial signposts: Q1 revenue was SEK 34.6 million (product sales SEK 33.9 million), down 48% year‑over‑year from SEK 66.3 million; Q1 SG&A was ~SEK 106 million (essentially flat vs Q4’25 at SEK 102M), R&D ~SEK 57 million, loss from operations SEK 143 million, cash used in operations SEK 157 million, headcount 122, and cash and cash equivalents ~SEK 677 million at quarter end; the company raised a USD 30 million convertible note (3% fixed interest, semiannual cash payments, maturity March 2031) and paid down ~SEK 15 million of NovaQuest debt with no further payment due until mid‑2027. They cautioned on continued quarter‑to‑quarter volatility from organ allocation but noted a strong start to Q2 and laid out near‑term milestones: PAES database lock next month, ConfIdeS full data and an oral ATC presentation in June, FDA feedback on the GBS (5487) briefing expected in May, a Capital Markets Day in June, a planned EMA full filing in Q4 and an expected PDUFA in December, plus a U.S. commercial build in Q4 targeting the top 100 centers (≈80% of volume) with 25 ConfIdeS centers accounting for ~25% of U.S. transplant volume.

Raised $30M Convertible Note Extending Runway

Entered a USD 30 million convertible note purchase agreement (fixed 3% interest, semiannual cash payments from Sep 15, 2026, maturity Mar 2031) on Mar 19, 2026, strengthening the balance sheet ahead of potential U.S. approval and launch.

Cash Position and Debt Reduction

Cash and cash equivalents totaled SEK 677 million at quarter end; paid down NovaQuest debt by ~SEK 15 million in January and have no additional payment due until mid-2027.

Regulatory and Clinical Milestones Progressing

BLA review with FDA initiated and described as progressing 'as expected' with no unusual questions; PAES database lock expected next month; ConfIdeS Phase III data accepted for oral presentation at ATC in June; plan to file for full EMA approval in Q4 and PDUFA in December.

Promising Next-Generation Program (5487) and GBS Development

First-in-human study of HNSA-5487 completed: >95% reduction in circulating IgG within hours, clear dose–response for duration, lower anti-drug antibody response vs imlifidase, safe and well tolerated; briefing submitted to FDA for GBS program with clinical phase planned to start by year-end pending FDA feedback expected in May.

Commercial Preparations for U.S. Launch

Full commercial build planned in Q4; focused U.S. site strategy on top 100 centers (approx. 80% transplant volume) with 25 ConfIdeS centers representing ~25% of volume; market-access planning ongoing (NTAP and Outlier payment strategies) and distribution/supply-chain arrangements in progress.

European Market Access Wins and Operational Improvements

Secured regional reimbursement in Catalonia effective Apr 1 (first sale post-Q1); German KOL consensus recommendations rolled out and submitted for publication (expected mid-2026); implemented new commercial systems (CRM, dashboards) and pan-European physician education to improve transparency and performance.

Cost Control in R&D

R&D expense in Q1 2026 totaled ~SEK 57 million, reported as 11% (SEK 7 million) favorable versus Q1 2024 (attributed to wind-down of certain clinical activities and 2025 restructuring).

Hansa Biopharma AB (SE:HNSA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SE:HNSA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 22, 2026	2026 (Q2)	-0.34 / -	-2.53	―	―	―
Apr 23, 2026	2026 (Q1)	-1.45 / -1.93	-0.55	-250.91% (-1.38)	―	―
Feb 11, 2026	2025 (Q4)	-1.58 / -1.62	-4.08	60.29% (+2.46)	―	―
Oct 30, 2025	2025 (Q3)	-1.74 / -1.75	-1.53	-14.38% (-0.22)	―	―
Jul 17, 2025	2025 (Q2)	-1.66 / -2.53	-3.3	23.33% (+0.77)	―	―
Apr 24, 2025	2025 (Q1)	-2.67 / -0.55	-4.15	86.75% (+3.60)	―	―
Feb 06, 2025	2024 (Q4)	-1.98 / -4.08	-2.4	-70.00% (-1.68)	―	―
Oct 17, 2024	2024 (Q3)	-2.42 / -1.53	-4.78	67.99% (+3.25)	―	―
Jul 18, 2024	2024 (Q2)	-2.78 / -3.30	-4.79	31.11% (+1.49)	―	―
Apr 18, 2024	2024 (Q1)	-3.46 / -4.15	-3.92	-5.87% (-0.23)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SE:HNSA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 23, 2026	kr27.12	kr24.88	-8.26%
Feb 11, 2026	kr36.98	kr38.74	+4.76%
Oct 30, 2025	kr34.46	kr30.66	-11.03%
Jul 17, 2025	kr25.94	kr27.90	+7.56%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Hansa Biopharma AB (SE:HNSA) report earnings?

Hansa Biopharma AB (SE:HNSA) is schdueled to report earning on Jul 22, 2026, Before Open (Confirmed).

What is Hansa Biopharma AB (SE:HNSA) earnings time?

Hansa Biopharma AB (SE:HNSA) earnings time is at Jul 22, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Hansa Biopharma AB stock?

The P/E ratio of Hansa Biopharma AB is N/A.

What is SE:HNSA EPS forecast?

SE:HNSA EPS forecast for the fiscal quarter 2026 (Q2) is -0.34.